Liver Disease
54 articles on Liver Disease, researched and written by the Shotlee Editorial Team from primary sources.
Semaglutide Greenlit for MASH Liver Disease Treatment
The MHRA has granted conditional approval for semaglutide to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis.
7 min read
Popular Weight-Loss Drugs Ozempic and Wegovy May Slow Biological Aging
A new clinical trial suggests that semaglutide, the active ingredient in Ozempic and Wegovy, may help slow biological processes associated with aging in adults with HIV.
8 min read
GLP-1 Medications for Obesity: Experts See a Broader Revolution Ahead
While GLP-1 receptor agonists have significantly advanced obesity treatment, specialists highlight the evolving landscape of comprehensive, personalized care that integrates various therapeutic strategies.
6 min read
Medicare's $50 GLP-1 Weight Loss Drug Trial: Who Qualifies?
For many older Americans, the high cost of GLP-1 weight loss medications has been a significant barrier. Now, a new Medicare trial offers a lifeline, potentially making these life-changing drugs accessible for just $50 a month. This article breaks down what you need to know about the Medicare GLP-1 Bridge program, including who qualifies, which medications are covered, and the program's future.
8 min read
Ozempic & Wegovy for Kids? Doctor Warns of Dangers
While GLP-1 medications show promise for adult obesity, their use in children is raising significant concerns. A medical expert weighs in on the potential dangers and the critical need for specialist oversight.
7 min read
Wegovy's New Frontier: Tackling MASH with Semaglutide
The UK's MHRA has approved Wegovy (semaglutide) for treating MASH, a significant step forward for patients with metabolic-associated steatohepatitis and liver fibrosis. This article delves into the details of this approval, the drug's mechanism, and its implications.
6 min read
Beyond the Scale: Navigating GLP-1s for Older Adults
As GLP-1 medications become more accessible, older adults are asking: 'Am I too old?' This guide explores the nuances of using these powerful drugs for weight loss in seniors, emphasizing health over age.
7 min read
Ozempic, Wegovy & Mounjaro: Weighing Risks for Young Patients on GLP-1s
As GLP-1 medications gain traction for weight management, doctors are increasingly prescribing them to adolescents. While short-term benefits are evident, significant questions remain about the long-term implications for young, developing bodies and minds.
7 min read
Beyond the Hype: Navigating GLP-1s for Sustainable Health
As demand for GLP-1 medications soars, healthcare professionals emphasize a balanced, comprehensive approach to weight management and chronic disease treatment, focusing on sustainability and patient well-being.
7 min read
Beyond the Rx: Mastering Metabolic Health with or Without GLP-1s
GLP-1 medications have revolutionized weight loss and diabetes management, but true metabolic health hinges on sustainable lifestyle changes. Discover how to improve your health, with or without these powerful tools.
7 min read
Wegovy, Ozempic & Mounjaro: The Real Truth About Weight Loss Meds
A comprehensive guide to GLP-1 receptor agonists, understanding efficacy, managing side effects, and navigating the future of obesity treatment.
7 min read
Beyond Weight Loss: The Next Wave of GLP-1 Drugs
The revolutionary GLP-1 medications have transformed weight management, but the journey of innovation continues. Discover how upcoming drugs aim to enhance patient experience and outcomes.
7 min read
Ozempic, Wegovy, Mounjaro: Why Rhode Island Medicaid Must Cover Obesity Meds
Rhode Island's strategic health initiatives are commendable, but a recent budget proposal to cut Medicaid coverage for GLP-1 obesity treatments like Ozempic and Wegovy raises serious concerns. This decision, while seemingly a cost-saving measure, risks long-term health consequences and increased healthcare expenditures.
6 min read
Beyond Weight Loss: The Expanding Horizon of GLP-1 Therapies
GLP-1 agonists, famously known for Ozempic and Wegovy, are making waves beyond their initial indications. While weight loss and diabetes management remain key, researchers are uncovering a broader therapeutic potential for these powerful peptide therapies.
8 min read
Beyond BMI: Hidden Health Reasons Doctors May Decline Mounjaro or Wegovy
While BMI is a primary factor, a range of underlying health conditions and personal histories can lead to a doctor declining a prescription for popular weight loss medications like Mounjaro and Wegovy. Understanding these criteria is vital before seeking treatment.
7 min read
Beyond the Scale: Unpacking the 'Darth Vader' Effect of Rapid Weight Loss
A peculiar new side effect, dubbed the 'Darth Vader' effect, is emerging with rapid weight loss achieved through GLP-1 medications. This article delves into the phenomenon, its potential causes, and the critical need for a balanced approach to weight management.
7 min read
Beyond the Injection: The Future of GLP-1 Therapies
GLP-1 receptor agonists have revolutionized weight loss and diabetes management, but researchers are continuously seeking ways to enhance their delivery. This article delves into cutting-edge advancements, from nanocarriers to microneedles, aiming to make these powerful therapies more effective, tolerable, and convenient.
7 min read
Retatrutide: The Next Wave in Metabolic Peptide Therapy?
Discover Retatrutide, a groundbreaking peptide with triple-receptor activity, poised to redefine metabolic health and weight management strategies. Learn about its science, potential, and what it means for the future of wellness.
8 min read
Zabopegdutide Shows Promise in MASH and Fibrosis: A New Hope for Liver Health
New data from D&D Pharmatech's Phase 2 trial for zabopegdutide, a GLP-1/glucagon dual receptor agonist, reveals promising results for patients with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis. This development positions zabopegdutide as a potential contender in a growing market.
7 min read
Beyond the 'Bridal Glow': The Real Story of Mounjaro & Weight Loss
As 'Mounjaro brides' become a trend, an endocrinologist unpacks the medical realities, risks, and ethical concerns surrounding using powerful weight-loss medications for cosmetic pre-wedding transformations.
9 min read
Beyond Weight Loss: GLP-1s Show Promise Against Inflammation
Initially celebrated for their weight-loss efficacy, GLP-1 receptor agonists are now revealing a broader therapeutic scope. Emerging research suggests these powerful medications may offer significant benefits in combating inflammation and tissue damage, potentially transforming the management of chronic diseases.
6 min read
Beyond Willpower: Understanding Obesity's Metabolic Roots
Obesity is a complex, multi-organ disease, not a failure of willpower. This article delves into its metabolic underpinnings and outlines a practical approach to management, including modern medications and lifestyle adjustments.
7 min read
Beyond Weight Loss: Surprising Health Benefits of GLP-1 Drugs
While widely recognized for their effectiveness in weight management, GLP-1 receptor agonists are revealing a spectrum of profound health benefits. Discover how these groundbreaking medications are impacting cardiovascular health, kidney function, liver disease, and even potentially neurodegenerative conditions.
7 min read
GLP-1 Agonists: A New Frontier in Liver Disease Treatment
GLP-1 receptor agonists, renowned for their impact on type 2 diabetes and obesity, are now emerging as powerful allies in the fight against liver diseases like MASH and alcohol-associated liver disease. Discover how these groundbreaking medications are reshaping hepatology.
6 min read
GLP-1s, Liver Health, and Digestive Innovations: A Medical Update
This comprehensive update delves into groundbreaking research on GLP-1 receptor agonists and their impact on liver health, alongside crucial developments in inflammatory bowel disease (IBD) management and innovative approaches to digestive symptom relief. Discover how cutting-edge science is shaping patient care and explore practical implications for managing chronic conditions.
7 min read
PCOS Renamed PMOS: A New Era for Endocrine Health
Polycystic Ovary Syndrome (PCOS), a condition affecting millions of women, is undergoing a significant renaming to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change aims to better reflect the condition's complex interplay with endocrine and metabolic systems, potentially improving diagnosis and treatment.
8 min read
GLP-1 Drugs: Beyond Weight Loss – New Benefits and Risks Emerge
GLP-1 medications are revolutionizing weight management and diabetes care, but their impact extends far beyond the scale. This article delves into the emerging benefits and potential risks associated with these powerful drugs, offering a comprehensive overview for patients and healthcare providers.
8 min read
New Procedure May Combat Weight Regain After GLP-1s
Losing weight with GLP-1 medications like semaglutide and tirzepatide is a significant achievement, but maintaining that loss after stopping treatment presents a major challenge. A new experimental procedure, duodenal mucosal resurfacing (DMR), is showing remarkable potential in helping individuals keep the pounds off.
7 min read
GLP-1 Medications: Miracle Drug, Wellness Trend, or Vanity?
GLP-1 medications have surged from diabetes treatment to mainstream wellness. This article examines their medical benefits, potential downsides, and the evolving societal perception of weight loss.
7 min read
GLP-1 Medications & Weight Loss: What's Behind the Buzz?
The world of weight management has been significantly impacted by the emergence of GLP-1 receptor agonists. These medications, including popular drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), have garnered immense attention for their effectiveness in promoting weight loss and improving metabolic health. But what exactly are these drugs, how do they work, and what should individuals considering them know?
7 min read
Survodutide Shines: Dual GLP-1/Glucagon Agonist Shows Major Weight Loss
Zealand Pharma and Boehringer Ingelheim announced breakthrough Phase 3 results for survodutide, a dual GLP-1 and glucagon receptor agonist, demonstrating significant weight reduction and metabolic improvements in adults with obesity or overweight.
7 min read
GLP-1s Aid Health Even Without Weight Loss: New Evidence
While most people on GLP-1 medications like Wegovy experience significant weight loss, 10-15% are non-responders. Emerging research shows these drugs still improve liver health, reduce heart risks, and more—independent of weight changes. A new mouse study reveals why, challenging insurance requirements for weight loss thresholds.
5 min read
GLP-1s Benefit Non-Responders Without Weight Loss: New Evidence
While most people on GLP-1 medications like Wegovy experience dramatic weight loss, 10-15% are non-responders. Emerging research shows these drugs still deliver benefits for liver disease, heart health, and more—independent of the scale. A new study from Dr. Daniel Drucker's lab uncovers why.
5 min read
Ozempic Improves Liver Health Without Weight Loss, Study Finds
A groundbreaking study shows that Ozempic and Wegovy enhance liver health directly, bypassing the need for weight loss. Canadian researchers uncovered semaglutide's action on key liver cells, challenging old assumptions about GLP-1 therapies. This could transform care for metabolic liver diseases like MASH.
6 min read
Eli Lilly Warns of Counterfeit Mounjaro, Zepbound Risks from Impurities
Eli Lilly, maker of Mounjaro and Zepbound, has discovered critical impurities in counterfeit tirzepatide versions mixed with vitamin B12. These compounded drugs pose unknown risks due to chemical reactions and lack of FDA oversight. With one in eight Americans using GLP-1s, experts urge sticking to approved medications.
5 min read
Fat Cells Burn Energy for Heat: Next Weight Loss Frontier
Fat tissue isn't just storage—it's a dynamic organ that can burn energy as heat, opening new doors for weight loss beyond appetite-suppressing drugs like Ozempic and Wegovy. Researchers are targeting brown and beige fat to boost calorie burn without triggering hunger. This could be the next era in metabolic therapies.
4 min read
GLP-1 Drugs Like Ozempic Raise Bone and Tendon Injury Risks, Study Suggests
New research reveals GLP-1 medications like Ozempic may significantly elevate risks of bone disorders and tendon injuries. Analyzing nearly 150,000 patients, the study found 30% higher osteoporosis rates and 50% increased tendon rupture risks over five years. Experts urge bone density monitoring amid these findings.
5 min read
Mounjaro Sales Hit $7.4B as Regulators Ban Social Media Ads; Tirzepatide Link...
Eli Lilly reports Mounjaro sales skyrocketing to $7.4 billion in Q4 2026, driven by explosive GLP-1 demand. New 2026 research links tirzepatide to liver inflammation resolution and reduced heart failure risks. Meanwhile, UK regulators ban unauthorized social media promotions of these prescription drugs.
5 min read
GLP-1 Drugs for Obesity: Why Treatment is Lifelong Like Oprah's Story
Oprah Winfrey shared on her podcast that stopping GLP-1 injections led to significant weight regain, sparking debate on obesity treatment. Expert insights reveal these drugs treat a chronic condition, not just temporary weight loss. Learn the science, risks, and how to approach long-term success.
4 min read
Scotland GLP-1 Costs Surge: Mounjaro Price Hike Impact
Scotland's NHS spending on GLP-1 weight-loss injections like Mounjaro has skyrocketed to nearly £3 million monthly, fueled by surging prescriptions and a sudden Mounjaro price hike tied to US policy. These drugs offer profound benefits beyond weight loss, reducing risks of heart disease and more. Here's what patients need to know about access, costs, and real-world impact.
4 min read
Novo Nordisk GLP-1s: Ozempic, Wegovy, Rybelsus Guide
Novo Nordisk has redefined obesity and diabetes care with its GLP-1 powerhouse: semaglutide brands Ozempic, Wegovy, and Rybelsus. These injectables and oral options deliver substantial weight loss, glycemic control, and cardiovascular protection. Discover how they work, compare to competitors, and optimize your treatment.
4 min read
Naltrexone: Ozempic for Alcohol Cravings Explained
Naltrexone is gaining buzz as the 'Ozempic for alcohol' by blunting booze's euphoric reward, much like GLP-1 drugs curb food noise. This guide dives into its science, real-world use via the Sinclair Method, and clinical evidence for reducing intake. Learn if it's right for habitual drinkers aiming for moderation.
4 min read
Retatrutide Explained: Triple Agonist Weight Loss Drug
Retatrutide is exploding on TikTok among gym enthusiasts for its potent weight loss effects, but it's not FDA-approved yet. This guide breaks down its triple-hormone mechanism, compares it to semaglutide and tirzepatide, and warns of black market risks. Learn why experts urge caution.
4 min read
GLP-3s, Monthly Pens: Next Obesity Drugs Leap in 2026
GLP-1 drugs like Ozempic and Mounjaro have revolutionized weight loss, and the next wave—GLP-3s such as retatrutide—promises even greater results. Eli Lilly's phase 3 trial revealed up to 28.7% body weight loss in 48 weeks. Discover monthly injections, oral pills, and emerging indications for 2026.
3 min read
Cardiologist: GLP-1 Drugs Benefits Beyond Weight Loss for Heart, Liver
Cardiologist Dmitry Yaranov states GLP-1 drugs like Ozempic, Wegovy, and Mounjaro offer benefits far beyond weight loss. They enhance cardiovascular health, combat fatty liver disease, and improve blood sugar control in diabetes patients. These medications could redefine treatment for heart, liver, and metabolic diseases.
1 min read
Pre-GLP-1 Injections: Crucial Exams Physicians Recommend
GLP-1 injectable treatments have surged in popularity in India, prompting medical professionals to emphasize comprehensive diagnostic evaluations before initiating therapy. Key assessments cover metabolic health, organ function, and specific risks to guarantee patient safety. This approach underscores the importance of medical oversight for these potent medications.
5 min read
Unseen Effects: Potential Impacts of GLP-1 Weight Loss Medications
GLP-1 medications, while effective for weight loss, can have various side effects. Understanding these potential impacts is crucial for informed decision-making and patient care. These medications affect different parts of the body, leading to diverse reactions based on individual physiology.
7 min read
GLP-1 Agonist Market Surge: A Metabolic Shift Transforming Diabetes Treatment and Global Obesity Management
The GLP-1 agonist market is undergoing significant expansion, fundamentally changing how Type 2 Diabetes and obesity are addressed globally. This drug class, initially for glycemic control, has become a key therapeutic option for weight management and cardiovascular risk reduction. The rising popularity of these drugs has sparked a pharmaceutical boom, with focus shifting to advanced agonists offering even greater metabolic advantages.
4 min read
Can Overweight Pets Use Ozempic? UAE Vets Weigh In as Trial Begins
Obesity in pets is a growing concern, linked to various health issues. As weight-loss drugs gain popularity for humans, the possibility of using similar medications for pets is being explored. However, experts emphasize the importance of addressing the root causes of pet obesity through diet and exercise.
5 min read
Cleveland Clinic Reverses Type 2 Diabetes Using AI, Not GLP-1 Drugs
The Cleveland Clinic is utilizing an AI-powered approach to reverse type 2 diabetes. This innovative method focuses on creating a 'digital twin' of a patient's metabolism, leading to significant improvements in health markers and a reduction in medication dependence.
10 min read
Clinical Trial Indicates Eli Lilly's 3-Target Drug Achieves New Weight Loss Milestone for Obesity
A novel drug candidate from Eli Lilly, targeting three metabolic pathways, has shown impressive weight loss results in a late-stage clinical trial. The study revealed an average weight loss of 28.7% among participants. However, the trial also reported a notable rate of treatment discontinuation.
3 min read
Anticipating Large Profits: Ozempic Patent Expiration Sparks Indian Pharma Generics Race
With the impending expiration of the Ozempic and Wegovy patents, Indian pharmaceutical giants are gearing up for a significant opportunity in the generics market. Surging obesity rates across India are fueling the demand for affordable weight-loss solutions.
7 min read
Mounjaro Delivered: UAE App Introduces Weight-Loss Medication Delivery
A prominent home services company in the UAE has begun delivering weight-loss medications, indicating the sustained popularity of GLP-1 drugs. This move raises discussions about accessibility and safety when obtaining prescription drugs online.
4 min read
GLP-1 Weight Loss & Beyond: Understanding the Impact of Semaglutide & Metabolic Health
Curious about GLP-1 medications like Ozempic and their role in weight loss? This blog post dives into the science, potential benefits, and importance of understanding your metabolic health journey for long-term well-being.
3 min read